drugset / Trial / NCT00291707
Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer
Phase 1
Completed
40 enrolled
University of Pittsburgh
Bristol-Myers Squibb · collabEli Lilly and Company · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this Phase I study is to determine the safety and effectiveness of two chemotherapies drugs, Cetuximab and Pemetrexed (Alimta), when given in combination with radiation therapy.
Timeline
- Start
- 2006-03
- Primary completion
- 2008-03
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 350 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |